AN UNBIASED VIEW OF LDN-27219 AS A CANCER DRUG CANDIDATE

One significantly intriguing compound is LDN-27219. Even though most tTG inhibitors are built to bind to your protein crosslinking Energetic website, LDN-27219 in its place binds to your nucleotide binding pocket on the enzyme whilst it is in its shut-state conformation, and stabilizes that conformation to forestall crosslinking activity.78 Schneid